GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (FRA:1HM) » Definitions » Float Percentage Of Total Shares Outstanding

Adaptive Biotechnologies (FRA:1HM) Float Percentage Of Total Shares Outstanding : 77.86% (As of Sep. 27, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Adaptive Biotechnologies's float shares is 114.82 Mil. Adaptive Biotechnologies's total shares outstanding is 147.47 Mil. Adaptive Biotechnologies's float percentage of total shares outstanding is 77.86%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Adaptive Biotechnologies's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Adaptive Biotechnologies's Institutional Ownership is 51.18%.

Adaptive Biotechnologies Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Adaptive Biotechnologies's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=114.82/147.47
=77.86%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptive Biotechnologies Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (FRA:1HM) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
KYMR RGNX AMAM INBX KURA AKRO VERV NVAX IMTX NAMS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ADPT:USA 1HM:Germany
Address
1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Website
https://www.adaptivebiotech.com
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Adaptive Biotechnologies Headlines

No Headlines